Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Molina Healthcare (MOH - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Molina Healthcare is a member of the Medical sector. This group includes 847 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MOH is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for MOH's full-year earnings has moved 6.88% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that MOH has returned about 4.30% since the start of the calendar year. In comparison, Medical companies have returned an average of 0.74%. This shows that Molina Healthcare is outperforming its peers so far this year.
Looking more specifically, MOH belongs to the Medical - HMOs industry, which includes 11 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have lost about 8.67% so far this year, so MOH is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to MOH as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Molina Healthcare (MOH - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Molina Healthcare is a member of the Medical sector. This group includes 847 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. MOH is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for MOH's full-year earnings has moved 6.88% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that MOH has returned about 4.30% since the start of the calendar year. In comparison, Medical companies have returned an average of 0.74%. This shows that Molina Healthcare is outperforming its peers so far this year.
Looking more specifically, MOH belongs to the Medical - HMOs industry, which includes 11 individual stocks and currently sits at #55 in the Zacks Industry Rank. Stocks in this group have lost about 8.67% so far this year, so MOH is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to MOH as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MOH - FREE